• Explore /
  • Poster
  • / Phase I study of ABBV-399, a c-Met antibody-drug conjugate (ADC), as monotherapy and in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).

Phase I study of ABBV-399, a c-Met antibody-drug conjugate (ADC), as monotherapy and in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).

Abstract Poster

Authors

null

ERIC ANGEVIN

Institut Gustave Roussy, Villejuif, France

ERIC ANGEVIN , John H. Strickler , Colin D. Weekes , Rebecca Suk Heist , Daniel Morgensztern , John J. Nemunaitis , Xiaolin Fan , Juliette Beaulieu , Monica Motwani , Daniel E. Afar , Louie Naumovski , Karen Kelly

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Immunoconjugates

Clinical Trial Registration Number

NCT02099058

Citation

J Clin Oncol 35, 2017 (suppl; abstr 2509)

DOI

10.1200/JCO.2017.35.15_suppl.2509

Abstract #

2509

Poster Bd #

1

Abstract Disclosures

Similar Posters

First Author: Rebecca Suk Heist

First Author: Jonathan W. Goldman

First Author: Neil E. Faulkner

First Author: Timothy Larson